Massachusetts Wealth Management Acquires 230 Shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Massachusetts Wealth Management boosted its holdings in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 1.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,414 shares of the company’s stock after acquiring an additional 230 shares during the quarter. Massachusetts Wealth Management’s holdings in Invesco Biotechnology & Genome ETF were worth $1,225,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new stake in shares of Invesco Biotechnology & Genome ETF in the third quarter valued at about $295,000. IHT Wealth Management LLC raised its holdings in Invesco Biotechnology & Genome ETF by 14.7% during the 3rd quarter. IHT Wealth Management LLC now owns 12,124 shares of the company’s stock worth $847,000 after purchasing an additional 1,550 shares during the last quarter. HighTower Advisors LLC lifted its position in shares of Invesco Biotechnology & Genome ETF by 64.1% in the 3rd quarter. HighTower Advisors LLC now owns 7,101 shares of the company’s stock worth $494,000 after purchasing an additional 2,774 shares during the period. Howe & Rusling Inc. bought a new stake in shares of Invesco Biotechnology & Genome ETF in the 3rd quarter valued at $31,000. Finally, Creative Financial Designs Inc. ADV increased its position in shares of Invesco Biotechnology & Genome ETF by 5.6% during the third quarter. Creative Financial Designs Inc. ADV now owns 5,630 shares of the company’s stock worth $393,000 after buying an additional 299 shares during the period.

Invesco Biotechnology & Genome ETF Stock Up 0.3 %

PBE stock opened at $69.05 on Wednesday. The company’s fifty day simple moving average is $68.64 and its 200 day simple moving average is $69.21. Invesco Biotechnology & Genome ETF has a 12-month low of $59.32 and a 12-month high of $72.84. The firm has a market cap of $278.96 million, a price-to-earnings ratio of 17.12 and a beta of 0.88.

Invesco Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.